Related Experiment Video
Updated: Jul 12, 2026

06:04
Establishment and Confirmation of a Postnatal Right Ventricular Volume Overload Mouse Model
Published on: June 9, 2023
Quantitative ventricular volume changes after endoscopic third ventriculostomy in children with Dandy-Walker
Aashmi Chandrikaa Senthilkumaran1, Subhas Konar2, Kevin Jude Sudevan1
1Department of Neurosurgery, NIMHANS, Bangalore, India.
Summary
Endoscopic third ventriculostomy (ETV) effectively treats hydrocephalus in Dandy-Walker malformation (DWM) patients. Ventricular volume reduction after ETV correlates with positive clinical outcomes, unlike posterior fossa cyst changes.
Area of Science:
- Pediatric Neurosurgery
- Medical Imaging
- Congenital Malformations
Background:
- Hydrocephalus is common in Dandy-Walker malformation (DWM), affecting up to 80% of cases.
- Endoscopic third ventriculostomy (ETV) is a primary treatment, but data on volumetric changes are limited.
Purpose of the Study:
- To evaluate volumetric changes in the brain's ventricles and posterior fossa cyst after ETV in DWM patients.
- To correlate these volumetric changes with clinical outcomes.
Main Methods:
- Retrospective analysis of pediatric DWM patients who underwent primary ETV for hydrocephalus.
- Preoperative and postoperative MRI scans analyzed using semiautomated volumetry to measure ventricular and cyst volumes.
- Assessment of clinical improvement, stoma patency, and need for re-intervention.
Main Results:
- ETV demonstrated a 66.7% success rate in treating hydrocephalus in DWM patients.
- Significant reduction in supratentorial ventricular volume (25.2%) and posterior fossa cyst volume (19.2%) observed post-ETV.
- Ventricular volume reduction correlated with improved clinical outcomes, while cyst volume reduction did not consistently predict success.
Conclusions:
- ETV is an effective shunt-free treatment for hydrocephalus in most DWM patients.
- Supratentorial ventricular volume reduction is a key indicator of ETV success.
- Posterior fossa cyst regression is variable and not essential for favorable clinical outcomes.
